of either ferric maltol and some oral drugs. For oral drugs where reductions in bioavailability may cause clinically significant effects on its safety or efficacy, separate administration of ferric maltol from these drugs. Duration of separation may depend on the absorption of the medication concomitantly administered (eg, time to peak concentration, whether the drug is an immediate or extended release product).fesoterodineMonitor Closely (3)fesoterodine decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. fesoterodine decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor. pimozide increases effects of fesoterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.fexinidazoleMonitor Closely (1)fexinidazole will increase the level or effect of pimozide by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.Serious - Use Alternative (2)fexinidazole and pimozide both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval. fexinidazole will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.finerenoneMonitor Closely (1)pimozide will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed.fingolimodSerious - Use Alternative (1)fingolimod and pimozide both increase QTc interval. Contraindicated.flavoxateMonitor Closely (3)flavoxate decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor. pimozide increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.flecainideSerious - Use Alternative (1)flecainide and pimozide both increase QTc interval. Avoid or Use Alternate Drug.flibanserinMonitor Closely (2)pimozide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors. flibanserin, pimozide. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).fluconazoleContraindicated (2)fluconazole and pimozide both increase QTc interval. Contraindicated. fluconazole increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.Minor (1)fluconazole will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.fludrocortisoneMinor (1)fludrocortisone will decrease the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.fluoxetineContraindicated (2)fluoxetine and pimozide both increase QTc interval. Contraindicated. fluoxetine increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.fluphenazineContraindicated (1)fluphenazine and pimozide both increase QTc interval. Contraindicated.Monitor Closely (2)fluphenazine and pimozide both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. fluphenazine and pimozide both increase sedation. Use Caution/Monitor.flurazepamMonitor Closely (1)flurazepam and pimozide both increase sedation. Use Caution/Monitor.fluvoxamineSerious - Use Alternative (2)fluvoxamine increases toxicity of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. fluvoxamine and pimozide both increase QTc interval. Avoid or Use Alternate Drug.formoterolMonitor Closely (1)pimozide increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)formoterol and pimozide both increase QTc interval. Avoid or Use Alternate Drug.fosamprenavirContraindicated (1)fosamprenavir increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.Minor (1)fosamprenavir will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.fosaprepitantContraindicated (1)fosaprepitant increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.Serious - Use Alternative (1)fosaprepitant will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Risk of QT interval prolongation.foscarnetSerious - Use Alternative (1)foscarnet and pimozide both increase QTc interval. Avoid or Use Alternate Drug.fosphenytoinMinor (1)fosphenytoin will decrease the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.fostemsavirMonitor Closely (1)pimozide and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. frovatriptanMonitor Closely (1)frovatriptan, pimozide. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).gadobenateSerious - Use Alternative (1)gadobenate and pimozide both increase QTc interval. Contraindicated.ganaxoloneMonitor Closely (1)pimozide and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacinSerious - Use Alternative (1)gemifloxacin and pimozide both increase QTc interval. Contraindicated.gemtuzumabMonitor Closely (1)pimozide and gemtuzumab both increase QTc interval. Use Caution/Monitor.gilteritinibSerious - Use Alternative (1)gilteritinib and pimozide both increase QTc interval. Contraindicated.givosiranSerious - Use Alternative (2)givosiran will increase the level or effect of pimozide by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP1A2 substrates with givosiran. If unavoidable, decrease the CYP1A2 substrate dosage in accordance with approved product labeling. givosiran will increase the level or effect of pimozide by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.glasdegibSerious - Use Alternative (1)pimozide and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.glofitamabMonitor Closely (1)glofitamab, pimozide. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glofitamab causes release of cytokines that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. For certain CYP substrates, minimal changes in their concentration may lead to serious adverse reactions. If needed, modify therapy as recommended in the substrate's prescribing information. .glycerol phenylbutyrateMonitor Closely (1)glycerol phenylbutyrate will decrease the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index.glycopyrrolateMonitor Closely (1)pimozide increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.glycopyrrolate inhaledMonitor Closely (3)glycopyrrolate inhaled decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. glycopyrrolate inhaled decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor. pimozide increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.glycopyrronium tosylate topicalMonitor Closely (1)glycopyrronium tosylate topical, pimozide. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.goserelinContraindicated (1)goserelin increases toxicity of pimozide by QTc interval. Contraindicated. Increases risk of torsades de pointes.granisetronSerious - Use Alternative (1)granisetron and pimozide both increase QTc interval. Contraindicated.grapefruitSerious - Use Alternative (1)grapefruit increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.Minor (1)grapefruit will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.griseofulvinMinor (1)griseofulvin will decrease the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.guanfacineMonitor Closely (1)guanfacine, pimozide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.guselkumabMonitor Closely (1)guselkumab, pimozide. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of guselkumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.haloperidolContraindicated (1)haloperidol and pimozide both increase QTc interval. Contraindicated.Monitor Closely (2)haloperidol and pimozide both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. haloperidol and pimozide both increase sedation. Use Caution/Monitor.henbaneMonitor Closely (3)henbane decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. henbane decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor. pimozide increases effects of henbane by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.histrelinSerious - Use Alternative (1)histrelin increases toxicity of pimozide by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.homatropineMonitor Closely (3)homatropine decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. homatropine decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor. pimozide increases effects of homatropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.hydrocodoneSerious - Use Alternative (1)hydrocodone, pimozide. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.hydrocortisoneMinor (1)hydrocortisone will decrease the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.hydromorphoneMonitor Closely (1)hydromorphone and pimozide both increase sedation. Use Caution/Monitor.hydroxychloroquine sulfateSerious - Use Alternative (1)hydroxychloroquine sulfate and pimozide both increase QTc interval. Avoid or Use Alternate Drug.hydroxyzineMonitor Closely (1)hydroxyzine and pimozide both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)hydroxyzine and pimozide both increase QTc interval. Contraindicated.hyoscyamineMonitor Closely (3)hyoscyamine decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. hyoscyamine decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor. pimozide increases effects of hyoscyamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.hyoscyamine sprayMonitor Closely (3)pimozide increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. hyoscyamine spray decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. hyoscyamine spray decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor.ibuprofen/famotidineSerious - Use Alternative (2)ibuprofen/famotidine, pimozide. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. pimozide, ibuprofen/famotidine. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug.ibutilideContraindicated (1)ibutilide and pimozide both increase QTc interval. Contraindicated.idelalisibSerious - Use Alternative (1)idelalisib will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substratesiloperidoneMonitor Closely (3)iloperidone and pimozide both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. iloperidone and pimozide both increase sedation. Use Caution/Monitor. iloperidone increases levels of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.Serious - Use Alternative (1)iloperidone and pimozide both increase QTc interval. Avoid or Use Alternate Drug.imatinibMonitor Closely (1)imatinib increases levels of pimozide by decreasing metabolism. Use Caution/Monitor.imipramineContraindicated (1)imipramine and pimozide both increase QTc interval. Contraindicated.Monitor Closely (1)pimozide and imipramine both increase sedation. Use Caution/Monitor.incobotulinumtoxinAMonitor Closely (1)pimozide increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.indacaterol, inhaledMonitor Closely (1)indacaterol, inhaled, pimozide. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.indapamideContraindicated (1)indapamide and pimozide both increase QTc interval. Contraindicated.indinavirSerious - Use Alternative (1)indinavir increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.inotuzumabSerious - Use Alternative (1)inotuzumab and pimozide both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.ipratropiumMonitor Closely (3)ipratropium decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. ipratropium decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor. pimozide increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.isavuconazonium sulfateMonitor Closely (2)pimozide will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. isavuconazonium sulfate will increase the level or effect of pimozide by affecting hepatic enzyme CYP2E1 metabolism. Use Caution/Monitor.isofluraneSerious - Use Alternative (1)isoflurane and pimozide both increase QTc interval. Contraindicated.isoniazidMonitor Closely (1)isoniazid will increase the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)isoniazid increases levels of pimozide by decreasing metabolism.